In vitro inhibition of African swine fever virus topoisomerase II disrupts viral replication.
African swine fever virus (ASFV) is the etiological agent of a highly contagious and fatal disease of domestic pigs, leading to serious socio economic impact in affected countries. To date, neither a vaccine nor a selective anti viral drug are available for prevention or treatment of African swine fever (ASF) emphasizing the need for more detailed studies at the role of ASFV proteins involved in viral DNA replication and transcription. Notably, ASFV encodes for a functional type II topoisomerase (ASFV Topo II) and we recently showed that several fluoroquinolones (bacterial DNA topoisomerase inhibitors) fully abrogate ASFV replication in vitro. Here, we report that ASFV Topo II gene is actively transcribed throughout infection, with transcripts being detected as early as 2 hpi and reaching a maximum peak concentration around 16 hpi, when viral DNA synthesis, transcription and translation are more active. siRNA knockdown experiments showed that ASFV Topo II plays a critical role in viral DNA replication and gene expression, with transfected cells presenting lower viral transcripts (up to 89% decrease) and reduced cytopathic effect 66% when compared to the control group. Further, a significant decrease in the number of both infected cells (75.5% and viral factories per cell and in virus yields (up to 99.7% 2.5 log) was found only in cells transfected with siRNA targeting ASFV Topo II. We also demonstrate that a short exposure to enrofloxacin during the late phase of infection (from 15 to 1 hpi) induces fragmentation of viral genomes, whereas no viral genomes were detected when enrofloxacin was added from the early phase of infection (from 2 to 16 hpi) suggesting that fluoroquinolones are ASFV Topo II poisons. Altogether, our results demonstrate that ASFV Topo II enzyme has an essential role during viral genome replication and transcription, emphasizing the idea that this enzyme can be a potential target for drug and vaccine development against ASF.
Antiviral research